慢性乙型肝炎病毒感染者白细胞介素35水平升高

StephenW

Int J Med Sci. 2018 Jan 1;15(2):188-194. doi: 10.7150/ijms.21957. eCollection  2018.
Interleukin-35 Level Is Elevated in Patients with Chronic Hepatitis B Virus Infection.Cheng ST1, Yuan D2, Liu Y3, Huang Y3, Chen X4, Yu HB1, He L1, Jiang H1, Ren JH1, Chen J1.
Author information
1Key Laboratory of Molecular Biology for Infectious Diseases (Ministry of Education), The Second Affiliated Hospital, Chongqing Medical University, Chongqing Medical University, Chongqing, China.2Department of Neurosurgery, The Fifth People's Hospital of Chongqing, Chongqing, China.3Department of Infectious Diseases, The Second Affiliated Hospital, Chongqing Medical University, Chongqing, China.4Department of Clinical Laboratory, Zhuzhou Central Hospital, Zhuzhou, China.

AbstractBackgrounds: As one of the major public health problems, the hepatitis B virus (HBV) infection would activate the immune system. The outcome of HBV infection was affect significantly by the interactions between HBV and host immune response. Interleukins play important role in anti-viral immunity. Here we investigated the role of interleukin-35 (IL-35) in chronic HBV infection patients. Methods/Results: Serum IL-35 in 72 chronic hepatitis B virus infection patients and 41 healthy control subjects were analyzed by ELISA assay. The mRNA level of IL-35 in PBMCs was determined by RT-qPCR. In this study, we found that both protein and mRNA levels of IL-35 were significantly decreased in chronic HBV patients compared to the healthy controls. Furthermore, the statistical analysis found that serum IL-35 was significantly associated with HBV DNA (P =0.0158), ALT (P =0.0003), AST (P =0.0216), TB (P =0.0270) and AFP (P =0.0369). Importantly, correlation analysis also found that serum IL-35 level was negatively correlated with HBV DNA copies, ALT, AST, TB and AFP. Meanwhile, IL-35 treatment inhibited the level of HBV DNA, HBsAg and HBeAg in HepAD38 cells. Conclusion: Our study identified that IL-35 may be a novel marker associated with HBV infection and hepatocytes injury. These data suggested the potential use of IL-35 in the HBV treatment.


KEYWORDS: Hepatitis B virus; Interleukin-35

PMID:29333103PMCID:PMC5765732DOI:10.7150/ijms.21957

• 
  


• 
  

StephenW

Int J Med Sci。 2018年1月1日; 15（2）：188-194。 doi：10.7150 / ijms.21957。 eCollection 2018年。
慢性乙型肝炎病毒感染者白细胞介素35水平升高
程ST1，袁D2，刘Y3，黄Y3，陈X4，于HB1，何L1，江H1，任JH1，陈1 1。
作者信息

1
    重庆医科大学附属第二医院感染性疾病分子生物学重点实验室（重庆医科大学）
2
    重庆市第五人民医院神经外科
3
    重庆医科大学附属第二医院感染科，重庆，中国。
4
    株洲市中心医院检验科

抽象

背景：作为主要的公共卫生问题之一，乙肝病毒（HBV）感染会激活免疫系统。 HBV感染的结果受到HBV与宿主免疫反应之间相互作用的显着影响。白细胞介素在抗病毒免疫中发挥重要作用。在这里，我们调查了白细胞介素35（IL-35）在慢性HBV感染患者中的作用。方法/结果：采用ELISA法检测了72例慢性乙型肝炎病毒感染者和41名健康对照者的血清IL-35水平。通过RT-qPCR测定PBMC中IL-35的mRNA水平。在这项研究中，我们发现与健康对照相比，慢性HBV患者中IL-35的蛋白和mRNA水平均显着降低。此外，统计分析发现血清IL-35与HBV DNA（P = 0.0158），ALT（P = 0.0003），AST（P = 0.0216），TB（P = 0.0270）和AFP（P = 0.0369） 。相关分析还发现，血清IL-35水平与HBV DNA拷贝数，ALT，AST，TB，AFP呈负相关。同时，IL-35可抑制HepAD38细胞中HBV DNA，HBsAg和HBeAg的表达。结论：我们的研究发现IL-35可能是一种与HBV感染和肝细胞损伤相关的新型标志物。这些数据表明在HBV治疗中可能使用IL-35。
关键词：

乙型肝炎病毒;白细胞介素35

结论：
    29333103
PMCID：
    PMC5765732
DOI：

windu

现成的产品